530 related articles for article (PubMed ID: 31708296)
1. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
Necchi A; Raggi D; Gallina A; Madison R; Colecchia M; Lucianò R; Montironi R; Giannatempo P; Farè E; Pederzoli F; Bandini M; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Dehò F; Ali SM; Chung JH; Ross JS; Salonia A; Briganti A; Montorsi F
Eur Urol; 2020 Apr; 77(4):439-446. PubMed ID: 31708296
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
[TBL] [Abstract][Full Text] [Related]
3. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
[TBL] [Abstract][Full Text] [Related]
5. Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.
Bandini M; Ross JS; Raggi D; Gallina A; Colecchia M; Lucianò R; Giannatempo P; Farè E; Pederzoli F; Bianchi M; Colombo R; Gandaglia G; Fossati N; Marandino L; Capitanio U; Deho' F; Ali SM; Madison R; Chung JH; Salonia A; Briganti A; Montorsi F; Necchi A
J Natl Cancer Inst; 2021 Jan; 113(1):48-53. PubMed ID: 32516377
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.
Necchi A; Bandini M; Calareso G; Raggi D; Pederzoli F; Farè E; Colecchia M; Marandino L; Bianchi M; Gallina A; Colombo R; Fossati N; Gandaglia G; Capitanio U; Dehò F; Giannatempo P; Lucianò R; Salonia A; Madison R; Ali SM; Chung JH; Ross JS; Briganti A; Montorsi F; De Cobelli F; Messina A
Eur Urol; 2020 May; 77(5):636-643. PubMed ID: 31882281
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
8. Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
Briganti A; Gandaglia G; Scuderi S; Gallina A; Colombo R; Fossati N; Barletta F; Pellegrino A; Nocera L; Montorsi F; Necchi A
Eur Urol; 2020 May; 77(5):576-580. PubMed ID: 31911010
[TBL] [Abstract][Full Text] [Related]
9. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Urol Oncol; 2021 Apr; 39(4):235.e15-235.e21. PubMed ID: 33071107
[TBL] [Abstract][Full Text] [Related]
10. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study
Bandini M; Gibb EA; Gallina A; Raggi D; Marandino L; Bianchi M; Ross JS; Colecchia M; Gandaglia G; Fossati N; Pederzoli F; Lucianò R; Colombo R; Salonia A; Briganti A; Montorsi F; Necchi A
Ann Oncol; 2020 Dec; 31(12):1755-1763. PubMed ID: 32979511
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
12. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
[TBL] [Abstract][Full Text] [Related]
14. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
[TBL] [Abstract][Full Text] [Related]
15. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
[TBL] [Abstract][Full Text] [Related]
16. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
Weickhardt A; Foroudi F; Lawrentschuk N; Xie J; Sidhom M; Pal A; Grimison P; Zhang A; Ng S; Tang C; Hovey E; Chen C; Hruby G; Guminski A; McJannett M; Conduit C; Tran B; Davis ID; Hayne D
Eur Urol Oncol; 2024 Jun; 7(3):469-477. PubMed ID: 37806844
[TBL] [Abstract][Full Text] [Related]
18. Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy.
Campbell RA; Khanna A; Boorjian SA; Knorr J; Cox R; Nicholas M; Cheville J; Sharma V; Murthy PB; Tarrell R; Thapa P; Tollefson MK; Thompson RH; Frank I; Karnes RJ; Haber GP; Lee B
Clin Genitourin Cancer; 2024 Apr; 22(2):157-163.e1. PubMed ID: 38008690
[TBL] [Abstract][Full Text] [Related]
19. Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy.
McFadden J; Tachibana I; Adra N; Collins K; Cary C; Koch M; Kaimakliotis H; Masterson TA; Rice KR
Urol Oncol; 2024 Mar; 42(3):69.e11-69.e16. PubMed ID: 38267301
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
